Haemoglobin-based oxygen carriers: is the benefit worth the risk?
When blood is indicated but not available, haemoglobin-based oxygen carriers can sustain oxygen carriage in acute anaemia, expand circulating volume and improve rheology to ischaemic tissues. When blood is limited, not available or not an option, the risks associated with these carriers must be weighed against the risk of death.
Mackenzie
Colin F
CF
Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
D000208:Acute Disease; D000740:Anemia / Q000188:drug therapy*; D001802:Blood Substitutes / Q000009:adverse effects / Q000627:therapeutic use*; D006454:Hemoglobins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008301:Maleimides / Q000009:adverse effects / Q000627:therapeutic use*; D010100:Oxygen / Q000097:blood*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors
D001802:Blood Substitutes; D006454:Hemoglobins; D008301:Maleimides; C509893:PolyHeme; C493836:maleimide-polyethylene glycol-modified hemoglobin, MP4; C096798:HBOC 201; D011092:Polyethylene Glycols; D010100:Oxygen